Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.
Abstract
Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.
참고문헌 (15)
- Lazaros GA, "Primary myxofibrosarcoma of the left atrium: case report and review of the literature", Angiology, 59, pp.632~635 (2008)
- McMillan RR, "Recurrence patterns after resection of soft tissue sarcomas of the chest wall", Ann Thorac Surg, 96, pp.1223~1228 (2013)
- Kikuta K, "An analysis of factors related to recurrence of myxofibrosarcoma", Jpn J Clin Oncol, 43, pp.1093~1104 (2013)
- Goldberg SB, "Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial", Lancet Oncol, 17, pp.976~983 (2016)
- Zschabitz S, "Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation", Eur J Cancer, 76, pp.1~7 (2017)
- Rexer H, "First-line therapy in advanced renal cell carcinoma: a randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38", 15 of the AUO, 2017, pp.56, 509~511
- Bellmunt J, "Pembrolizumab as second-line therapy for advanced urothelial carcinoma", N Engl J Med, 376, pp.1015~1026 (2017)
- Fletcher CD, "World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone", pp.102~103 (2002), IARC Press
- Nascimento AF, "Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases", Am J Surg Pathol, 31, pp.99~105 (2007)
- Tumeh PC, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, 515, pp.568~571 (2014)
- Weide B, "Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab", Clin Cancer Res, 22, pp.5487~5496 (2016)
- Zhu Z, "Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis", Oncotarget, 8, pp.59570~59580 (2017)
- Kosemehmetoglu K, "Programmed death ligand 1 (PD-L1) expression in malignant mesenchymal tumors", Turk Patoloji Derg, 1, pp.192~197 (2017)
- Tawbi HA, "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial", Lancet Oncol, 18, pp.1493~1501 (2017)
- D'Angelo SP, "A multi-center phase II study of nivolumab +", - ipilimumab for patients with metastatic sarcoma (Alliance A091401), 2017, pp.35(Suppl), ~